Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13872493 | 0.81 | LCK (0.46) | LCKLMNAHPGDHSD17B10CSNK2A2 | |
| SCHEMBL4139190 | 0.80 | KDM4E (0.56) | LMNAHPGDMAPTMEN1KMT2A | |
| SCHEMBL4139066 | 0.78 | MAPK8 (0.58) | LCKSMN1; SMN2HPGDMAPK1MAPT | |
| SCHEMBL4146645 | 0.76 | TYMS (0.50) | SMN1; SMN2LMNAHPGDMAPTMEN1 | |
| SCHEMBL7969645 | 0.75 | LCK (0.84) | LCK | |
| SCHEMBL7969972 | 0.75 | LCK (0.78) | LCK | |
| SCHEMBL4931040 | 0.74 | LCK (1.00) | LCKSMN1; SMN2LMNAHPGDMAPK1 | |
| SCHEMBL4139033 | 0.72 | ALDH1A1 (0.43) | LMNAHPGDHSD17B10MAPTKDM4E | |
| SCHEMBL4134603 | 0.72 | ALDH1A1 (0.43) | SMN1; SMN2LMNAHPGDHSD17B10MAPT | |
| SCHEMBL11910203 | 0.70 | MAP4K4 (0.44) | SMN1; SMN2MAPK1HSD17B10MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093476-A1 | PYRROLO[1,2-A]QUINOXALINE DERIVATIVES AS ADENOSINE A3 RECEPTOR MODULATORS AND USES THEREOF | FAUST PHARMACEUTICALS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093476-A1 | PYRROLO[1,2-A]QUINOXALINE DERIVATIVES AS ADENOSINE A3 RECEPTOR MODULATORS AND USES THEREOF | FAUST PHARMACEUTICALS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093476-A1 | PYRROLO[1,2-A]QUINOXALINE DERIVATIVES AS ADENOSINE A3 RECEPTOR MODULATORS AND USES THEREOF | FAUST PHARMACEUTICALS (FR) | 2009-04-09 | — | — | US | disclosed |
| WO-2007071379-A1 | PYRROLO [l,2-A]QUINOXALINE DERIVATIVES AS ADENOSINE A3 RECEPTOR MODULATORS AND USES THEREOF | FAUST PHARMACEUTICALS (FR) | 2007-06-28 | — | — | WO | disclosed |
| EP-1798233-A1 | Pyrrolo[1,2-a]quinoxaline derivatives as Adenosine A3 receptor modulators and uses thereof | Faust Pharmaceuticals (FR) | 2007-06-20 | — | — | EP | disclosed |
| EP-1798233-A1 | Pyrrolo[1,2-a]quinoxaline derivatives as Adenosine A3 receptor modulators and uses thereof | Faust Pharmaceuticals (FR) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093476-A1 | PYRROLO[1,2-A]QUINOXALINE DERIVATIVES AS ADENOSINE A3 RECEPTOR MODULATORS AND USES THEREOF | ADORA3, ADORA2A, ADORA1 | LCK 3626/4885SMN1; SMN2 4266/4885LMNA 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.